{"id":46635,"date":"2022-07-27T16:01:53","date_gmt":"2022-07-27T14:01:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bio-300-pharmacokinetics-studies-published\/"},"modified":"2022-07-27T16:01:53","modified_gmt":"2022-07-27T14:01:53","slug":"bio-300-pharmacokinetics-studies-published","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bio-300-pharmacokinetics-studies-published\/","title":{"rendered":"BIO 300 Pharmacokinetics Studies Published"},"content":{"rendered":"
\n

\nStudies compared multiple routes of administration with and without radiation exposure<\/i>\n<\/p>\n

MINNEAPOLIS–(BUSINESS WIRE)–A recently published paper<\/a> in Radiation Research<\/i>, the official journal of the Radiation Research Society, details the results from a series of pharmacokinetics (PK) studies conducted with Humanetics Corporation\u2019s (Humanetics) new radioprotective drug, BIO 300. The studies, which were conducted by researchers at the University of Maryland Schools of Medicine and Pharmacy (UMB), compared the PK of BIO 300 using oral, subcutaneous, and intramuscular dosing. These nonclinical studies also examined the effect of radiation exposure on the PK of BIO 300. The researchers concluded that the effect of irradiation on the PK of BIO 300 is minimal, an important finding for use of the drug during radiation emergencies or during cancer radiotherapy treatments.\n<\/p>\n

<\/a><\/p>\n

\nExposure to radiation can lead to acute radiation syndrome (ARS), which consists of numerous serious and life-threatening injuries. Survivors of ARS are at risk of developing delayed effects of acute radiation exposure (DEARE), which include a multitude of chronic injuries, notably to the lungs. There are currently no FDA-approved drugs that prevent ARS or DEARE. Humanetics is developing BIO 300 as a medical countermeasure (MCM) for use by the military, first responders, and in civilian populations that have been exposed, or may become exposed, to radiation to prevent or mitigate both ARS and DEARE.\n<\/p>\n

\n\u201cOur ongoing collaboration with colleagues at UMB has been instrumental in the development of BIO 300 for use as a MCM,\u201d said Ronald Zenk, CEO of Humanetics. \u201cCurrent events in Ukraine and global threats of nuclear incidents point to the urgent need for drugs like BIO 300.\u201d\n<\/p>\n

\nBIO 300 is also in clinical development for oncology applications to protect cancer patients from unintentional side effects caused by radiation therapy. Humanetics recently completed a phase 1b\/2a clinical trial in lung cancer patients (NCT02567799<\/a>). In addition, a phase 2b trial is currently in progress evaluating the clinical utility of BIO 300 to protect lung tissues against the long-term effects of COVID-19 (NCT04482595<\/a>).\n<\/p>\n

\nAbout Humanetics Corporation<\/b>\n<\/p>\n

\nHumanetics is a clinical-stage specialty pharmaceutical company engaged in the accelerated discovery, development, and commercialization of proprietary drugs in markets with urgent and unmet needs, with a focus on medical countermeasures to prevent harm caused by exposure to radiation, for protective use in cancer radiation therapy, and to guard against the long-term damaging effects of COVID-19. For more information, visit www.humaneticscorp.com.<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nJohn Dykstra
\n
Humanetics Corporation
\n
JDykstra@Humaneticscorp.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Studies compared multiple routes of administration with and without radiation exposure MINNEAPOLIS–(BUSINESS WIRE)–A recently published paper in Radiation Research, the official journal of the Radiation Research Society, details the results from a series of pharmacokinetics (PK) studies conducted with Humanetics Corporation\u2019s (Humanetics) new radioprotective drug, BIO 300. The studies, which were conducted by researchers at … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46635","6":"format-standard","7":"category-industry"},"yoast_head":"\nBIO 300 Pharmacokinetics Studies Published - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/bio-300-pharmacokinetics-studies-published\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BIO 300 Pharmacokinetics Studies Published - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Studies compared multiple routes of administration with and without radiation exposure MINNEAPOLIS–(BUSINESS WIRE)–A recently published paper in Radiation Research, the official journal of the Radiation Research Society, details the results from a series of pharmacokinetics (PK) studies conducted with Humanetics Corporation\u2019s (Humanetics) new radioprotective drug, BIO 300. The studies, which were conducted by researchers at ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/bio-300-pharmacokinetics-studies-published\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-27T14:01:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220727005194\/en\/821286\/21\/humlogo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-300-pharmacokinetics-studies-published\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-300-pharmacokinetics-studies-published\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BIO 300 Pharmacokinetics Studies Published\",\"datePublished\":\"2022-07-27T14:01:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-300-pharmacokinetics-studies-published\\\/\"},\"wordCount\":402,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-300-pharmacokinetics-studies-published\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220727005194\\\/en\\\/821286\\\/21\\\/humlogo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-300-pharmacokinetics-studies-published\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-300-pharmacokinetics-studies-published\\\/\",\"name\":\"BIO 300 Pharmacokinetics Studies Published - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-300-pharmacokinetics-studies-published\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-300-pharmacokinetics-studies-published\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220727005194\\\/en\\\/821286\\\/21\\\/humlogo.jpg\",\"datePublished\":\"2022-07-27T14:01:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-300-pharmacokinetics-studies-published\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-300-pharmacokinetics-studies-published\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-300-pharmacokinetics-studies-published\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220727005194\\\/en\\\/821286\\\/21\\\/humlogo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220727005194\\\/en\\\/821286\\\/21\\\/humlogo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bio-300-pharmacokinetics-studies-published\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BIO 300 Pharmacokinetics Studies Published\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BIO 300 Pharmacokinetics Studies Published - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/bio-300-pharmacokinetics-studies-published\/","og_locale":"en_US","og_type":"article","og_title":"BIO 300 Pharmacokinetics Studies Published - Pharma Trend","og_description":"Studies compared multiple routes of administration with and without radiation exposure MINNEAPOLIS–(BUSINESS WIRE)–A recently published paper in Radiation Research, the official journal of the Radiation Research Society, details the results from a series of pharmacokinetics (PK) studies conducted with Humanetics Corporation\u2019s (Humanetics) new radioprotective drug, BIO 300. The studies, which were conducted by researchers at ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/bio-300-pharmacokinetics-studies-published\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-27T14:01:53+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220727005194\/en\/821286\/21\/humlogo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/bio-300-pharmacokinetics-studies-published\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/bio-300-pharmacokinetics-studies-published\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BIO 300 Pharmacokinetics Studies Published","datePublished":"2022-07-27T14:01:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bio-300-pharmacokinetics-studies-published\/"},"wordCount":402,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bio-300-pharmacokinetics-studies-published\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220727005194\/en\/821286\/21\/humlogo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/bio-300-pharmacokinetics-studies-published\/","url":"https:\/\/pharma-trend.com\/en\/bio-300-pharmacokinetics-studies-published\/","name":"BIO 300 Pharmacokinetics Studies Published - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bio-300-pharmacokinetics-studies-published\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bio-300-pharmacokinetics-studies-published\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220727005194\/en\/821286\/21\/humlogo.jpg","datePublished":"2022-07-27T14:01:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/bio-300-pharmacokinetics-studies-published\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/bio-300-pharmacokinetics-studies-published\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/bio-300-pharmacokinetics-studies-published\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220727005194\/en\/821286\/21\/humlogo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220727005194\/en\/821286\/21\/humlogo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/bio-300-pharmacokinetics-studies-published\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BIO 300 Pharmacokinetics Studies Published"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46635"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46635\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}